Bruce C. Cozadd Sells 1,500 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the transaction, the chief executive officer now directly owns 439,744 shares in the company, valued at approximately $53,785,088.64. This represents a 0.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Jazz Pharmaceuticals Stock Down 0.1 %

Jazz Pharmaceuticals stock opened at $121.53 on Thursday. The firm has a market capitalization of $7.35 billion, a PE ratio of 17.12, a P/E/G ratio of 0.90 and a beta of 0.56. The company’s 50-day moving average is $122.60 and its 200-day moving average is $116.32. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $134.17. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Pacer Advisors Inc. grew its stake in Jazz Pharmaceuticals by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock valued at $272,713,000 after buying an additional 115,102 shares during the last quarter. Franklin Resources Inc. grew its stake in Jazz Pharmaceuticals by 4.6% in the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock valued at $124,208,000 after buying an additional 48,708 shares during the last quarter. Thompson Siegel & Walmsley LLC grew its stake in Jazz Pharmaceuticals by 8.3% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 781,215 shares of the specialty pharmaceutical company’s stock valued at $87,035,000 after buying an additional 59,685 shares during the last quarter. Perpetual Ltd grew its stake in Jazz Pharmaceuticals by 10.4% in the 3rd quarter. Perpetual Ltd now owns 675,431 shares of the specialty pharmaceutical company’s stock valued at $75,250,000 after buying an additional 63,564 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Jazz Pharmaceuticals by 8.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 531,710 shares of the specialty pharmaceutical company’s stock valued at $59,238,000 after buying an additional 42,587 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analysts Set New Price Targets

JAZZ has been the topic of a number of recent analyst reports. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. Robert W. Baird boosted their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $163.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Finally, TD Cowen cut their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $177.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.